Standard BioTools Inc.
NASDAQ:LABMedical - Devices
+$0.03 today
- Market cap
- $225.03M
- Beta
- 1.38
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.24
Volume 0.70M
Average 2.91M
LAB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Standard BioTools Inc.NASDAQ: LAB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $2.12M fell 61.1% year over year, behind the -43.6% change in trailing-twelve-month research & development. Sequentially, it fell 72.8% from the prior quarter. Over 3 fiscal years it compounded at -11.4% a year.
Context
- Research & development amounted to 30.5% of revenue in FY2025, down 5.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -61.1% toward the trailing-twelve-month pace of -43.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 25.99M USD
- Year-over-year change
- -58.4%
- 4-year CAGR
- -9.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.99M | -58.4% |
| FY2024 | 2024-12-31 | 62.41M | +140.5% |
| FY2023 | 2023-12-31 | 25.95M | -30.6% |
| FY2022 | 2022-12-31 | 37.38M | -1.5% |
| FY2021 | 2021-12-31 | 37.94M | — |
Research & Development vs competitors
How LAB compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -43.6% is the lowest of 11, against a peer median of -7.5%.
- Research & development amounts to 26.1% of revenue for LAB, versus a peer median of 9.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $188.07M USD | +22.3% | +26.8% | — | |
| LTM Mar 2026 | CN¥128.61M CNY | -18.4% | -17.2% | 7.8% | |
| LTM Mar 2026 | $94.95M USD | -15.8% | -17.7% | 119.9% | |
| LTM Apr 2026 | $89.5M USD | +0.1% | +5.8% | 10.4% | |
| LTM Mar 2026 | $36.35M USD | -7.6% | +1.5% | 17.8% | |
| LTM Mar 2026 | $22.9M USD | -6.9% | -8.9% | 3.2% | |
| LTM Mar 2026 | $22.48M USD | -43.6% | -11.4% | 26.1% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $21.06M USD | +43.4% | +38.3% | 22.2% |
| LTM Mar 2026 | $19.34M USD | -7.4% | +14.3% | 9.3% | |
| LTM Mar 2026 | $11.57M USD | -19.0% | -20.2% | 2.0% | |
| LTM Mar 2026 | $8.98M USD | -13.5% | +2.5% | 3.7% | |
| Peer median (excluding LAB) | — | -7.5% | +2.0% | 9.3% | |
Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 130.58M | 97.95M | 106.34M | 174.43M | 85.33M |
| Cost of Revenue | 61.21M | 60.9M | 55.89M | 90.17M | 42.79M |
| Gross Profit | 69.37M | 37.05M | 50.45M | 84.26M | 42.54M |
| Gross Margin | 53.1% | 37.8% | 47.4% | 48.3% | 49.9% |
| Research & Development | 37.94M | 37.38M | 25.95M | 62.41M | 25.99M |
| Selling, General & Admin | 98.89M | 102.29M | 87.54M | 156.61M | 109.86M |
| Operating Expenses | 136.83M | 153.26M | 127.05M | 259.5M | 135.85M |
| Depreciation & Amortization | 15.57M | 15.03M | 15.18M | 16.86M | 6.98M |
| EBITDA | (44.27M) | (173.57M) | (54.46M) | (118.14M) | (89.69M) |
| EBITDA Margin | -33.9% | -177.2% | -51.2% | -67.7% | -105.1% |
| Operating Income | (67.46M) | (116.21M) | (76.6M) | (175.24M) | (93.31M) |
| Operating Margin | -51.7% | -118.6% | -72.0% | -100.5% | -109.3% |
| Interest Income | 0 | 2.23M | 5.57M | 20.2M | 9.18M |
| Interest Expense | 3.82M | 4.33M | 4.57M | 3.32M | 26K |
| Other Income / Expenses | 3.8M | (76.72M) | 2.4M | 36.92M | (3.4M) |
| Income Before Tax | (63.66M) | (192.93M) | (74.2M) | (138.31M) | (96.7M) |
| Pre-Tax Margin | -48.8% | -197.0% | -69.8% | -79.3% | -113.3% |
| Income Tax Expense | (4.42M) | (2.83M) | 452K | 573K | (37.88M) |
| Net Income | (59.24M) | (190.1M) | (74.66M) | (138.89M) | (74.9M) |
| Net Margin | -45.4% | -194.1% | -70.2% | -79.6% | -87.8% |
| EPS (Basic) | (0.78) | (2.43) | (0.94) | (0.52) | (0.20) |
| EPS (Diluted) | (0.78) | (2.43) | (0.94) | (0.52) | (0.20) |
| Weighted Avg Shares | 75.79M | 78.31M | 79.16M | 352.67M | 381.62M |
| Weighted Avg Shares (Diluted) | 75.79M | 78.31M | 79.16M | 352.67M | 381.62M |
Standard BioTools Inc.
NASDAQ:LAB
Intrinsic Alpha fair value
Locked
Current Price
$0.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.